Nearly Half of Patients With LGS Experience 50% or Greater Seizure Reduction With Perampanel A meta-analysis showed perampanel leads to clinically meaningful seizure reduction in LGS, although with variable durability.

#Perampanel (#Fycompa®) provides clinically meaningful seizure reduction in patients with Lennox‑Gastaut syndrome (#LGS), with 46.5% of patients experiencing at least a 50% reduction in seizure frequency.

Learn more: https://bit.ly/3NnKXlG

#RareDisease #LennoxGastautSyndrome #MedSky